Rad Tech CE, ASRT, ARRT® CE, Category A Credits | Radiology Continuing Education

Approvals/Requirements Satisfied by eRADIMAGING Courses

  • ASRT approval for ARRT Category A credit
  • All Courses eligible of international radiographers' CPD requirements
  • ASRT and MDCB are approved continuing education providers of ARRT and all courses are accepted by ARRT
  • California CE requirements met for all radiography courses
  • NMTCB accepted (All Courses)
  • All Courses available for RRAs
  • ARMRIT accepted (All MRI Courses)
  • MDCB approval by the Medical Dosimetrist Certification (Selected Courses)
  • Florida approval for all courses 1 credit or more
  • ARDMS accepted (All Courses)
  • CAMRT and Sonography Canada recognize the ASRT approval (All Courses)
  • Approval: This course is approved by ASRT and MDCB - approved continuing education providers of ARRT.
  • Release Date: 11/1/2006
  • Expiration Date: 12/1/2010
  • Credit Hours: 0.5 Credits
  • Course Description and objectives:

    Course Description

    Prostate cancer is the second most common form of cancer among men, following only skin cancer. Early detection significantly increases the likelihood of long-term survival. However, the widely used prostate-specific antigen test (PSA), a blood serum test used to detect prostate cancer, is the subject of much debate. Although the incidence of prostate cancer has decreased in recent years, it is unclear how much of this effect can be attributed to PSA screening. Experts disagree on the need for the test, in addition to its effectiveness. Elevated PSA levels may indicate changes in the prostate unrelated to malignancy, producing patient anxiety and prompting physicians to prescribe treatment for conditions that might never be life-threatening. Professional societies, such as the American Cancer Society and the American Urologic Association, have developed different guidelines regarding the role of PSA assessment in cancer screening. Refinements to the PSA test have been made over the past 2 decades, but more research is needed to develop a tumor marker that would better identify aggressive cancers.

    Learning Objectives

    After reading this article, participants should be able to:

    • Understand how the prostate-specific antigen (PSA) test works in identifying patients with prostate cancer.
    • Discuss the debate over the effectiveness of the PSA test in identifying tumors that must be aggressively treated from tumors that require monitoring of progress.
    • Explain new screening methods and the need for a better marker.

  • CE Information:

    Continuing Education Information 

    In order to receive CE credit, you must first complete the activity content. When completed, go to the "CE Test" link to access the post-test.

    Submit the completed answers to determine if you have passed the post-test assessment. You must obtain a score of 75% to receive the CE credit. You will have no more than 3 attempts to successfully complete the post-test.

    Participants successfully completing the activity content and passing the post-test will receive .5 ARRT Category A credit.

    Approved by the American Society of Radiologic Technologists for ARRT Category A credit.

    Approved by the Medical Dosimetrist Certification Board for MDCB credit.

    This activity may be available in multiple formats or from different sponsors. ARRT does not allow CE activities, such as Internet courses, home study programs, or directed readings to be repeated for CE credit in the same or any subsequent biennium.


Prostate-Specific Antigen Test: Is It a Valid Screening Tool for Prostate Cancer?

Pamela C. Cartright, MAEd, RT(R)(T)

   *Director, Radiation Therapy Program, Diagnostic and Therapeutic Sciences, University of Alabama at Birmingham, Birmingham, Alabama.
   Address correspondence to: Pamela C. Cartright, MAEd, RT(R)(T), Director, Radiation Therapy Program, Diagnostic and Therapeutic Sciences, University of Alabama at Birmingham, RMSB 436, 1705 University Boulevard, Birmingham, AL 35294. E-mail: pamcartr@uab.edu.

ABSTRACT 

Prostate cancer is the second most common form of cancer among men, following only skin cancer. Early detection significantly increases the likelihood of long-term survival. However, the widely used prostate-specific antigen test (PSA), a blood serum test used to detect prostate cancer, is the subject of much debate. Although the incidence of prostate cancer has decreased in recent years, it is unclear how much of this effect can be attributed to PSA screening. Experts disagree on the need for the test, in addition to its effectiveness. Elevated PSA levels may indicate changes in the prostate unrelated to malignancy, producing patient anxiety and prompting physicians to prescribe treatment for conditions that might never be life-threatening. Professional societies, such as the American Cancer Society and the American Urologic Association, have developed different guidelines regarding the role of PSA assessment in cancer screening. Refinements to the PSA test have been made over the past 2 decades, but more research is needed to develop a tumor marker that would better identify aggressive cancers.

View the full content

Sample eRADIMAGING Course *

* This sample course is for reference purposes only. It is not currently available for earning CE credits. To earn ARRT CE credits please subscribe to eRADIMAGING where you will see a complete listing of all active and eligible CE courses.

Become a member

Satisfy your CE requirements today!

Join now

We offer special group rates, call or email.

984.227.8560

support@eradimaging.com

Newsletter

Enter your email address to receive our new course alerts.